Apps have thrived in the mental health space, especially during the pandemic. Here are different options that range in prices and functionality.
Navigating the mental health system is no easy feat. Throw in a pandemic and things grow a little more digital and way more complicated. Luckily, there are apps out there working hard to connect you with experts in ways that are faster and much less expensive than a traditional therapy session.
These options provide different kinds of digital connections, whether they’re through texting, crisis lines, or talk therapy apps. Although there’s not much data out there on how effective these apps actually are, they’re an efficient way of speaking with a professional, especially if you find yourself in a crisis and need some help.
This app offers a variety of different plans ranging from $65-$99 a week that include everything from low-key text options to more involved video sessions and direct connections to mental health experts. Talkspace provides different tools, such as a progress tracker and exercises to develop coping skills.
7 Cups is another paid app that connects you with experts and volunteers. By filling out a questionnaire where you address which topics you’d like to answer, the app asks you if you’d like to be connected with a listener or a therapist, and things move from there. Membership is $150 per month.
What’s Up is one of the few apps that is free to use, suggesting different methods for coping with depression, anxiety, and more, all following Cognitive Behavioral Therapy (CBT) and Acceptance Commitment Therapy (ACT) techniques. The app features a tracker for positive and negative behaviors and page that helps you spot and recognize your thinking patterns.
Mood Kit is another app for mild symptoms of depression and anxiety. It follows CBT, and comes with more than 200 mood improvement activity recommendations. It’s a good app for practicing self-care whether you’re feeling down or are simply looking to work on improving your personal habits.
This app was developed by a struggling teen and his brother and features a big red button that you can press and alarm your friends and loved ones that you need their help. Users can select up to five contacts to be a part of their support group. These contacts will receive the emergency message and a GPS location of the user’s phone.
Gov. Jared Polis meant it as a joke, but Ohio’s Mike DeWine has long maintained he won’t legalize cannabis under any circumstances.
If you can’t beat them, might as well hypnotize them. That was the joke Colorado Gov. Jared Polis made over the weekend in a Reddit Ask Me Anything session. Polis, who has hosted several AMAs, used the opportunity to answer questions about Colorado’s COVID-19 response, opening state parks again in Colorado, and more.
Polis also answered several drug policy questions, including a specific request from a user.
“Can you convince my governor here in Ohio to allow recreational marijuana?” user Pioneer411 asked Polis.
“Sure, at the next National Governors Assoc. meeting I will hypnotize him and plant the suggestion deep in his psyche,” Polis responded.
While clearly a joke, the suggestion speaks to Ohio Gov. Mike DeWine’s intransigence against marijuana legalization. Marijuana advocacy group NORML gave DeWine an “F” score on its annual NORML gubernatorial scorecard, citing the governor’s public position against the legalization of cannabis. DeWine re-asserted this stance in January as nearby states like Michigan legalized.
Ohio has a medical marijuana program through H.B. 523 that allows access to patients with qualifying conditions, including cancer, epilepsy, PTSD, chronic pain, and more. But 30% of registered patients haven’t purchased anything at an Ohio dispensary, complaining program rules inhibit them from purchasing what they need.
Photo by Bailey Starner via Unsplash
The criticism led to a recreational marijuana drive in the state and organizers submitted a petition to the Attorney General earlier this year. The petition was rejected, due to its language and lack of support. Advocates have until July to change the amendment proposal and gather more than 440,000 valid signatures.
CBD is easy to use, yet it’s very important to understand a few things before you make your first purchase.
Incorporating CBD into your life is pretty simple. The compound has plenty of relaxing benefits that should fit neatly with the world’s current stressful environment, helping you to cope with anxiety, depression, and physical pain. Before you make the leap, however, there are a few things you should be aware of.
The CBD industry is relatively new. Although the compound is very promising and newsworthy, there’s not a lot of scientific study that supports it, which means that buyers should be extra careful when browsing for products because there’s a ton of misinformation out there.
Here are some simple dos and don’ts when it comes to buying your first CBD product:
Buying CBD is not like buying a t-shirt or a new brand of shampoo. Thanks to the relative newness of the product and the fact that the government is still behind on product testing, there are a lot of loopholes that many businesses are trying to take advantage of. Since CBD is so popular, many companies are making CBD products that don’t contain CBD, are misleading with their information, and don’t follow the proper safety guidelines. Do your research on CBD products that have verified results, endorsed by people you trust and that have plenty of reviews from all kinds of users.
Don’t buy the first product you stumble upon
Since CBD is so popular, you’ll likely find products anywhere, from convenience stores, eBay, Amazon and more. Before you make a purchase, make sure that you trust them. Here’s a helpful guide that can assist you and ensure that the CBD products you’re considering are safe and actually do what they’re meant to do.
Reading product labels is not easy, not even when it’s a common household item. CBD labels are even more complex, differing depending on the state that issues them and the type of product they are. When reading a CBD label, look for the amount of CBD in the product, the dosage, the oil source and a COA analysis. This analysis ensures that the product was tested by a third party, which is a lab that has no connection with the product makers. (You can read more on how to read CBD labels.)
Don’t buy all of the information that’s out there
There’s a ridiculous amount of CBD products out there, from oils, creams, transdermal patches, to CBD infused workout clothes and pillowcases. While the compound has some promise in certain areas, there comes a point when you have to draw a line and face the fact that a lot of companies are simply after your money. Do your research, look for a CBD product that targets the ailment you’re trying to find relief from and enjoy yourself. Do your best to tune out the noise because there’s a lot of it.
If a WTO member country legalizes a product domestically, its justifications for restricting international transactions might not succeed under WTO law.
Last year, we helped a client take a hard look at an issue related to cannabis and the World Trade Organization (WTO). It was a fascinating project and WTO lawyers took preliminary interest in the issue. We were told that cannabis had not come before the WTO in any formal or informal context to that point, whether for market access or other issues. Moreover, there were no WTO working groups related to cannabis, no real reports, no recommendations and no “disciplines.” As far as we know, all of that is true today.
What exactly is the WTO and what does it do? The WTO is a multilateral organization governing trade among nations, based on obligations its member states undertake through various treaties. The WTO is the largest international economic organization in the world. It’s also kind of new, having formed via the the Marrakesh Agreement in 1994. According to that Agreement, the purpose of the WTO is “the substantial reduction of tariffs and other barriers to trade and… the elimination of discriminatory treatment in international trade relations.” The WTO administers a complex legal regime regulating international trade, and WTO member countries must abide by these rules. Otherwise, they can be dragged before WTO’s dispute settlement body (sued, basically).
When it comes to cannabis, it’s important to note that the WTO recently clarified (and even emphasized) in an Appellate Body Report that “illicit trade” is not exempt from WTO disciplines. This means that the WTO legal framework permits member countries to ban trade in products that are also prohibited domestically. However, if a WTO member legalizes a product domestically, its justifications for restricting international transactions might not succeed under WTO law. More and more countries are legalizing cannabis domestically, to various degrees.
Let’s look at a few examples of how this could work: one with respect to “market access” issues, and one on “national treatment”, the two primary categories of WTO dispute resolution.
The market access example for cannabis is based on a recent WTO dispute related to tobacco. Suppose Mexico finally gets its act together and puts the finishing touches on federal cannabis legalization in 2020. And suppose Mexican companies wish to export beautifully packaged cannabis chocolate to Canada (another country that has legalized cannabis federally). Canada tells Mexico it won’t accept the chocolate, because Canada has essentially adopted “plain packaging” regulations for cannabis based on public health concerns. Mexico could bring this issue to the WTO, challenging Canada’s “technical barriers to trade” and obstacles related to trademark registration. The WTO would parse these claims in the context of various treaties, including but not limited to TBT, TRIPS and probably even USMCA. That would be a fun dispute.
Photo by Esther Kelleter/EyeEm/Getty Images
Next is the national treatment example. Let’s say a WTO member country with a CBD export economy, like Bulgaria, accused another WTO CBD country, like the U.S., of “unfair treatment as to a like product.” Bulgaria might argue that the U.S. is unlawfully supporting or subsidizing its CBD industry in some fashion. Or, it might argue that U.S. FDA governance as to CBD is merely a pretext for economic favoritism. These types of “vice product” disputes come up frequently before the WTO. Also fun.
It’s important to note that the WTO does not exist solely to resolve disputes. Sometimes the WTO takes on modernization projects if a new commodity comes to market. Other times, it serves as a trade policy “think tank” of sorts: member states gather to hash out topics, recommend rules and explore new disciplines (just like in regional trade agreements). In general, though, the WTO is viewed as more reactive than proactive in most respects. When the organization does engage, a core philosophy seems to be that “markets should be open” and restraints on trade should be viewed skeptically.
When WTO finally picks up cannabis, it will look closely at relevant treaties joined by member states. Those treaties will include WTO agreements, such as TRIPS and TBT , regional trade agreements, and also treaties like the U.N. Single Convention on Narcotic Drugs. It will contend with health reports promulgated by the World Health Organization and other bodies, and defer to those treaties extensively. The role of WTO is not to recommend policy, after all. Instead, it examines what other authorities have produced, and it considers member state trade policies in light of those reports and recommendations.
The WTO will engage the international cannabis trade somehow, some way, in the next few years. It will be fascinating to watch that play out.
Vince Sliwoski is an attorney at Harris Bricken, a law firm with lawyers in Seattle, Portland, Los Angeles, San Francisco, Barcelona, and Beijing. This story was originally published on the Canna Law Blog.
It’s now a widely-held and recognized belief that cannabis helps patients with epilepsy maintain a better quality of life and find respite from seizures.
With the Centers for Disease Control (CDC) citing that epilepsy affects over 3.4 million Americans, identifying a key function in the disease’s ability to target certain parts of the body gives researchers key insight into understanding how and why epilepsy occurs. In a new studypublished in the Annals of Neurology, researchers found that an autoantibody, which works against the body, seems to be responsible for causing epilepsy in some patients. While examining encephalitis (epilepsy) and its effect on the brain, researchers at the University of Bonn in Germany found that a few distinct patterns of epilepsy included inflammation inside the brain, leading them to find scientific evidence of epilepsy’s effect on brain activity and functionality.
Discovered in the spinal fluid of patients battling epilepsy, the autoantibody interacts with a protein called Drebrin, which is a conduit between nerve cells to ensure they function well. Without functionality, these nerve cells can misfire, triggering responses by seizures. Identifying the autoantibody and how it attacks the brain is one way scientists and researchers can unlock the secrets of epilepsy.
In 2018, the U.S. Food and Drug Administration (FDA) approved the cannabidiol medicine EPIDIOLEX® to treat seizures associated with epilepsy. This recent study offers greater hope to patients trying to find relief as well.
Photo by sudok1/Getty Images
States have come far in their legalization over the past five years. One father’s plight, published in WIRED, showcases the many miles and heartbreaks that faced one father as he attempted to find a solution to his son’s 100+ daily seizures.
CBD has already been identified as a key tool in the fight against seizures that come with epilepsy and The Epilepsy Foundation believes it’s a valuable asset in any patient’s toolbox. They state, “In recent years, a number of studies have shown the benefit of specific plant-based CBD products in treating specific groups of people with epilepsy who have not responded to traditional therapies.” The peer-reviewed journal Practical Neurologystated in 2018 that “The general population appears to be showing a fundamental and rapid shift in its opinion regarding cannabis and cannabis-related drugs.” In just two years’ time, it’s now a widely-held and recognized belief that cannabis helps patients with epilepsy maintain a better quality of life and find respite from seizures.
Republican backlash over the SAFE Banking Act questions whether the legislation has any chance of passing.
The cannabis industry applauded this week as federal lawmakers added provisions in the latest round of coronavirus aid aimed at marijuana companies. While the HEROES Act did not open cannabis businesses to Small Business Administration (SBA) loans and grants, it did include the SAFE Banking Act. The bill, passed last year in the House but stalled in the Senate, would allow banks to provide financial services to the cannabis industry without fear of federal prosecution.
“I just learned the #SAFEBankingAct is included in the CARES 2.0 package,” Rep. Ed Perlmutter wrote on Twitter. “I have been pushing for this because the #COVID19 crisis has only exacerbated the risk posed to cannabis businesses & their employees & they need relief just like any other legitimate business.”
The enthusiasm was short-lived. Following the announcement, the Senate Republican Conference (SRC) deconstructed the HEROES Act and called out provisions they described as advantageous legislation. “Here are some items Speaker Pelosi decided to include in her political-pipe-dream of a bill,” @SenateGOP tweeted out.
Senate Republicans labeled the SAFE Banking Act as part of Pelosi’s “political-pipe-dream of a bill.” This led some to assume this part of the legislation would never pass through the GOP-controlled Senate. But the tweet has since been deleted after Senate Republicans realized Republican Sen. Cory Gardner is a lead sponsor of the SAFE Banking Act.
The question on the minds of marijuana advocates then has become whether the SAFE Banking Act has a chance of passing as part of coronavirus aid.
“I would have said no, but when the Senate Republican Conference tweeted criticism, they pulled it down when they realized that Cory Gardner is a major sponsor and is in a tough re-election campaign,” David Feldman, a partner at the global law firm Hiller P.C., told The Fresh Toast. “So I would probably still say unlikely but not impossible.”
Photo by ultramarine5/Getty Images
Smart Approaches to Marijuana (SAM), an anti-legalization group, added sand to the smoldering ember with a full-throated declaration against the provision.
“Numerous industries have been forced to completely shut down and have made great sacrifices to comply with shutdowns and limitations on their business operations,” SAM CEO Kevin Sabet said in a statement. “The marijuana industry has been a painfully obvious exception to this. This industry has used its lobbying arm to force state officials to keep their storefronts open, sued leaders who shut them down, and bragged incessantly about their revenues.”
States have deemed marijuana businesses “essential” under quarantine orders and allowed to stay open while governors have introduced legalization as a way to kickstart local economies in the wake of the coronavirus pandemic.
It seems likely that cannabis will end up like alcohol, only monitored for actual abuse with corresponding treatment options and monetary fines depending on number of offenses.
Anyone who knows me knows that I really enjoy sports of all kinds. I was a college soccer player and played competitive club soccer in Florida before that from the age of 7 onward (and I now play in an adult co-ed league in Los Angeles). Unfortunately, COVID-19 has put the damper on watching live professional sports on TV, and clearly no one can attend any sporting events right now or likely anytime soon. Pro athletes have time on their hands now to train and/or rest up accordingly, which got me to thinking about our pro leagues’ treatment of cannabis and how it has evolved over recent years.
I recall when it was a pretty big deal that Seattle and Denver were playing each other in the Super Bowl six years ago, since both teams’ states legalized cannabis in 2012 (and they played the game in Jersey, which also had cannabis legal reform for medical use). More recently, in 2018 the question arose whether cannabis ads would be allowed to take up coveted Super Bowl TV ad space, as the teams–the Pats and the Eagles–hailed from states with serious cannabis legal reform.
For the longest time, it seemed like professional leagues were not going to acknowledge the reality that their players were not only consuming cannabis for various health and relaxation reasons. Instead, they were willing to put their heads in the sand regarding state-by-state legalization.
Most player contracts, collective bargaining agreements, and league policies and player rules dictated that cannabis consumption (or even participating in a cannabis business) would carry stiff consequences for players where cannabis remains federally illegal. However, many professional athletes have openly admitted to using cannabis and even more have done branding, licensing, and joint venture deals in the state legal cannabis industry as part of their livelihoods. So to maintain antiquated, punitive anti-cannabis consumption and/or business participation policies at the pro level seemed draconian and out of touch at best.
This post is a departure from my regular legal analysis of the various business issues that seem to constantly arise for cannabis entrepreneurs. Instead, I’ll be visiting the most recent cannabis consumption/business policies for the Big Four sports leagues, set forth below.
National Hockey League (NHL)
Photo by Bruce Bennett/Staff/Getty Images
The NHL was a first mover on more relaxed cannabis consumption policies for players. And it’s no wonder–according to ESPN:
“Of the 31 teams in the NHL, 28 play in states where players have access to legal marijuana, whether it is for medicinal or recreational purposes. That’s the highest percentage (90.3) of any of the major four North American pro leagues, but hardly an anomaly.”
The National Hockey League Players’ Association (NHLPA) is the labor union representing athletes in the NHL, and it handles grievances as well as negotiating with the league on rules and procedures, including guidelines for drug testing (as do all Players Associations in the Big Four). The NHL has a pretty relaxed drug testing policy around THC in its athletes. In particular, NHL players are randomly and anonymously drug tested throughout the season with an “all drug” screening. Only if a player shows “dangerously high levels” of THC in their system (by the way, THC and CBD aren’t even on the banned drug list) that the league and NHLPA take notice and flags the athlete for treatment, which is not meant to be disciplinary in nature. While the NHL and NHLPA don’t encourage cannabis use, they aren’t affirmatively trying to stop players from consuming and THC isn’t a banned substance in the NHL anyway.
Major League Baseball (MLB)
Photo by Doug Pensinger/Staff/Getty Images
Late last year, the MLB took the major step of removing cannabis from the banned substances list for players, and that policy took effect this year. At the same time, the league, in concert with its Players Association added various opioids to the list to better protect players from drug abuse. The MLB affirmatively decided that cannabis consumption (despite federal law) would be treated the same as alcohol. Players flagged for using cannabis on drug screens will “be referred to a treatment board under specific conditions,” and they cannot be punished for failing to participate in a recommended treatment program.
National Basketball Association (NBA)
Photo by tookapic via Pixabay
The NBA is way behind the NHL and MLB on its cannabis consumption policies for players, though the league and its Players Association seem to both agree that more progressive treatment of cannabis is now warranted (when David Stern was the league commissioner, his opinion was that cannabis should be off of the banned substances list altogether).
In the NBA, cannabis is still on the banned substances list and just 15 nanograms per milliliter of THC is considered a positive drug test (players have to take 4 random tests a season for cannabis). Punishment for testing “hot” escalates from drug treatment to significant monetary fines to multi-game suspensions depending on the number of failed tests. Current commissioner Adam Silver has not yet moved to get cannabis off of the League’s banned substances list, but it looks like he could be persuaded from the medical use vantage point, and the Player’s Association also seems supportive of its removal to ensure player protection around not only health and wellness but also for curbing unwarranted arrests for possession.
National Football League (NFL)
Photo by Doug Pensinger/Staff/Getty Images
In March of this year, the NFL finally eased some of its rules around cannabis consumption for players (before this, it was probably worse than the NBA and was pretty aggressive with enforcing the policy and punishments). Per the New York Times:
“Under the new collective bargaining agreement [which was ratified on March 15, 2020], players who test positive for marijuana will no longer be suspended. Testing will be limited to the first two weeks of training camp instead of from April to August, and the threshold for the amount of 9-delta tetrahydrocannabinol — or THC, the psychoactive compound in marijuana — needed to trigger a positive test will be raised fourfold.”
Players can still be fined, depending on the number of drug tests they fail related to THC intake (and first-time offenders, like with MLB and the NHL, will be referred to treatment in a drug rehabilitation program with the threat of game suspensions if they don’t participate).
———–
Overall, the Big Four (and their corresponding Players Associations) have moved in the right direction in the last five years on cannabis testing, with the NHL and MLB having the most enlightened and progressive policies of all. Just like the states, it seems that the Big Four will either treat cannabis as truly medicinal and allow (or forego punishment) for players’ use; and it seems likely that cannabis will end up like alcohol, only monitored for actual “abuse” with corresponding treatment options and monetary fines depending on number of “offenses.”
Uh oh. A survey shows that both singles and those in relationships have been using dating apps more often.
Despite the fact that people have been spending more time alone than ever before, there’s been an increase in dating app use. These apps, such as Tinder, report that users have been discussing quarantine topics more often, with apps facilitating video chats and phone calls for all users.
Another interesting finding is that people in relationships who are quarantined apart from their partners have also started downloading these apps, even spending more time than single people while browsing and looking at other potential hookups.
A survey, commissioned by luxury sex toy brand LELO and conducted by OnePoll, asked 1,000 single Americans and 1,000 Americans in relationships who are spending these months apart from their partners, about their app usage and found some interesting results.
“While 41% of single people said they’ve signed up for a dating website during their isolation, a surprising 52% of attached Americans signed up as well,” explains the report.
“It’s only natural people are missing the intimacy they had prior to the pandemic. All the things we took for granted are now conspicuously missing from our lives,” says LELO’s Luka Matutinovic.
Photo by Kon Karampelas via Unsplash
Singles and those in relationships have reached out to their ex while in quarantine and have also become less picky about the people who they are choosing to chat with. “Six out of ten people say they are willing to lower their standards and talk to someone outside their ‘usual type’ while in isolation,” says the report.
When it comes to embracing virtual dates, a topic that has caused people a significant amount of stress, 27% of single people report taking the plunge. Forty-one percent of people in relationships report having virtual dates with their significant other, which is kind of low number. It’s been two months, people.
The “Facebook” of marijuana announced in a press release they’d received a $50,000 cash infusion via the SBA’s PPP loan.
The House announced this week that marijuana businesses were included in the latest round of coronavirus-related federal aid. However, that doesn’t mean cannabis companies will receive loans from the Small Business Administration. Instead, the SAFE Banking Act, which protects banks providing financial services to cannabis companies from federal penalties, was among the legislation.
Marijuana companies are ineligible for SBA funding services, because cannabis is a federally illegal substance. At least that is what many companies have been told. But marijuana technology company MassRoots announced in a press release last week it had received a $50,000 loan under the payment protection program. The release comes at a suspicious time for MassRoots, as the company was just sued by the SEC for stock fraud manipulation, according to Green Market Report.
“I’m pleased to report MassRoots has raised significant capital to fund our operations and, later this month, launch our rewards program – MassRoots Rewards – aimed at driving cannabis demand from our community to client dispensaries,” stated Massroots CEO Isaac Dietrich.
As Cannabis.net notes, Dietrich is conspicuously excluded from the SEC lawsuit against major shareholders of MassRoots, which was once called the “Facebook” of cannabis. “While the SEC claimed to be assisted by an unnamed source in the papers, Isaac was not charged with anything at this point,” reads the Cannabis.net report.
Photo by Josh Appel via Unsplash
Previously, legal experts said ancillary cannabis companies could receive SBA funding if they could prove they don’t touch the plant. MassRoots received the majority of funding last year from institutional investors, with only 3% coming from cannabis businesses. Dietrich told Law360 he used part of the loan to pay rent and five employees while the rest of the loan will be saved for payroll purposes.
“We’ve slashed our monthly expenses to less than $75,000 per month, negotiated far better rates and terms with our vendors, and built a rewards model we believe can gain widespread adoption while generating positive cash-flows,” Dietrich stated. “We’ve learned many important lessons in the five years since MassRoots became a public company – and we’re now positioned to combine that knowledge with an unparalleled work-ethic to deliver results for all our shareholders.”
With the anti-inflammation properties of CBD and marijuana, it’s only a matter of time before scientists start experimenting with THC’s effects on the body and its genomes.
Could marijuana and CBD be helped by a genomic parasite to decrease inflammation and viruses?
Researchers at the CECAD Cluster of Excellence in Aging Research of the University of Cologne, University of Texas Health Science Center and the Francis Crick Institute in London have made a significant discovery that offers insight into targeting viruses and inflammation alike through identifying a key protein called, ZBP1.
Published in the journal Nature, the scientists found that ZBP1, a protein best known for defending against incoming viruses, is activated by sensing an unusual form of cellular genetic material (Z-nucleic acids), leading to cell death and inflammation.
Found in Z-nucleic acids, ZBP1 is a cellular genetic material; double-strained DNA and RNA molecules with an, “unusual left-handed double helix structure.” Discovered over 4 decades ago, scientists have been attempting to understand how the protein unlocks a feature that harms viruses in its path. Once ZBP1 is activated, it can “sense” the genetic make-up of viruses, identifying threats and activating a kill sequence not only when a virus is present but when it meets its kryptonite: RIPK1, a protein stopping ZBP1.
ZBP1, not only seems to have a hand in helping the body fight viruses but seems to offer positive effects on inflammatory diseases such as arthritis. Experimenting on models of mice, researchers were able to showcase that the, “ZBP1 protein binds to double-stranded RNA,” explained Manolis Pasparakis, a professor in the study. “Just like during viral infection, sensing of Z-RNA produced by endogenous retroelements by ZBP1 could provide a potent trigger for cell death and inflammation, and cause disease.
These are early days and we have a long way to go, but understanding the underlying mechanisms may one day lead to novel therapies for human diseases.”
With the anti-inflammation properties of CBD and marijuana, it’s only a matter of time before scientists start experimenting with THC’s effects on the body and its genomes. Cited as a “novel anti-inflammatory,” cannabis has been researched for decades for its ability to heighten the body’s immune system and relax inflammation. A 2009 study published in the peer-reviewed journal Future Medicinal Chemistry, stated that, “The cannabinoid system has been shown both in vivo and in vitro to be involved in regulating the immune system through its immunomodulatory properties. Cannabinoids can either directly inhibit tumor growth or suppress inflammation and tumor angiogenesis.” One thing is certain: With new medical research comes the ability to deeper understand the human body’s genetic makeup, offering key insights to how cells react. It’s a matter of if, not when scientists unlock the human body’s many secret abilities.
